Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study

Christian Torp-Pedersen; Harry J G M Crijns; Christophe Gaudin; Richard L Page; Stuart J Connolly; Stefan H Hohnloser; ATHENA Investigators

doi:10.1093/europace/eur102

Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study

Christian Torp-Pedersen, Harry J G M Crijns, Christophe Gaudin, Richard L Page, Stuart J Connolly, Stefan H Hohnloser, ATHENA Investigators

35 Citationer (Scopus)

Abstract

Cardiovascular (CV) hospitalization is a predictor of CV mortality and has a negative impact on patients' quality of life. The primary endpoint of A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENTs with Atrial fibrillation/atrial flutter (ATHENA), a composite of first CV hospitalization or death from any cause, was significantly reduced by dronedarone. This post hoc analysis evaluated the secondary endpoint of CV hospitalization and the clinical benefit of dronedarone on the number and duration of CV hospitalizations in patients with atrial fibrillation (AF).

Originalsprog	Engelsk
Tidsskrift	Europace
Vol/bind	13
Udgave nummer	8
Sider (fra-til)	1118-26
Antal sider	9
ISSN	1099-5129
DOI	https://doi.org/10.1093/europace/eur102
Status	Udgivet - 2011

Adgang til dokumentet

10.1093/europace/eur102

Citationsformater

@article{51a46619158d4538a1e4b4de0e233b83,

title = "Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study",

abstract = "Cardiovascular (CV) hospitalization is a predictor of CV mortality and has a negative impact on patients' quality of life. The primary endpoint of A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENTs with Atrial fibrillation/atrial flutter (ATHENA), a composite of first CV hospitalization or death from any cause, was significantly reduced by dronedarone. This post hoc analysis evaluated the secondary endpoint of CV hospitalization and the clinical benefit of dronedarone on the number and duration of CV hospitalizations in patients with atrial fibrillation (AF).",

keywords = "Aged, Amiodarone, Anti-Arrhythmia Agents, Atrial Fibrillation, Female, Follow-Up Studies, Hospitalization, Humans, Incidence, Intensive Care, Kaplan-Meier Estimate, Length of Stay, Male, Recurrence",

author = "Christian Torp-Pedersen and Crijns, {Harry J G M} and Christophe Gaudin and Page, {Richard L} and Connolly, {Stuart J} and Hohnloser, {Stefan H} and {ATHENA Investigators}",

year = "2011",

doi = "10.1093/europace/eur102",

language = "English",

volume = "13",

pages = "1118--26",

journal = "Europace",

issn = "1099-5129",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - Impact of dronedarone on hospitalization burden in patients with atrial fibrillation

T2 - results from the ATHENA study

AU - Torp-Pedersen, Christian

AU - Crijns, Harry J G M

AU - Gaudin, Christophe

AU - Page, Richard L

AU - Connolly, Stuart J

AU - Hohnloser, Stefan H

AU - ATHENA Investigators

PY - 2011

Y1 - 2011

N2 - Cardiovascular (CV) hospitalization is a predictor of CV mortality and has a negative impact on patients' quality of life. The primary endpoint of A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENTs with Atrial fibrillation/atrial flutter (ATHENA), a composite of first CV hospitalization or death from any cause, was significantly reduced by dronedarone. This post hoc analysis evaluated the secondary endpoint of CV hospitalization and the clinical benefit of dronedarone on the number and duration of CV hospitalizations in patients with atrial fibrillation (AF).

AB - Cardiovascular (CV) hospitalization is a predictor of CV mortality and has a negative impact on patients' quality of life. The primary endpoint of A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENTs with Atrial fibrillation/atrial flutter (ATHENA), a composite of first CV hospitalization or death from any cause, was significantly reduced by dronedarone. This post hoc analysis evaluated the secondary endpoint of CV hospitalization and the clinical benefit of dronedarone on the number and duration of CV hospitalizations in patients with atrial fibrillation (AF).

KW - Aged

KW - Amiodarone

KW - Anti-Arrhythmia Agents

KW - Atrial Fibrillation

KW - Female

KW - Follow-Up Studies

KW - Hospitalization

KW - Humans

KW - Incidence

KW - Intensive Care

KW - Kaplan-Meier Estimate

KW - Length of Stay

KW - Male

KW - Recurrence

U2 - 10.1093/europace/eur102

DO - 10.1093/europace/eur102

M3 - Journal article

C2 - 21576129

SN - 1099-5129

VL - 13

SP - 1118

EP - 1126

JO - Europace

JF - Europace

IS - 8

ER -

Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater